Werewolf Therapeutics Financials - Benzinga

Werewolf Therapeutics Inc

HOWLNASDAQ

Trade with Public

Trade with Public

$0.3987

-0.0033-0.82%

Last update: Aug 6, 2:41 PM

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Werewolf Therapeutics Financials

Werewolf Therapeutics (HOWL) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Werewolf Therapeutics Q2 EPS $0.08 Beats $(0.29) Estimate, Sales $21.000M

Werewolf Therapeutics (NASDAQ:HOWL) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $(0.29) by 127.59 percent. This is a 120 percent increase over losses of $(0.40) per share

Benzinga Newsdesk

PRO
Werewolf Therapeutics Q1 EPS $(0.28), Inline

Werewolf Therapeutics (NASDAQ:HOWL) reported quarterly losses of $(0.28) per share which met the analyst consensus estimate. This is a 30 percent increase over losses of $(0.40) per share from the same period last year.

Benzinga Newsdesk

Earnings Scheduled For March 27, 2026

Benzinga Insights

PRO
Werewolf Therapeutics Q4 EPS $(0.20) Beats $(0.35) Estimate

Werewolf Therapeutics (NASDAQ:HOWL) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.35) by 43.18 percent. This is a 56.52 percent increase over losses of $(0.46) per share

Benzinga Newsdesk

PRO
Werewolf Therapeutics Q3 EPS $(0.36) Beats $(0.39) Estimate

Werewolf Therapeutics (NASDAQ:HOWL) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.39) by 7.69 percent. This is a 5.26 percent increase over losses of $(0.38) per share

Benzinga Newsdesk

PRO
Werewolf Therapeutics Q2 EPS $(0.40) Beats $(0.48) Estimate

Werewolf Therapeutics (NASDAQ:HOWL) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.48) by 17.36 percent. This is a 6.98 percent increase over losses of $(0.43) per share

Benzinga Newsdesk